Method of capturing CRISPR endonuclease cleavage products
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention is a method of capturing DNA ends formed by endonuclease cleavage, such as CRISPR endonuclease cleavage, for downstream analysis including amplification and sequencing.
Core Innovation
The described method captures a target nucleic acid from a sample containing target and non-target nucleic acids. It uses CRISPR Cas9 cleavage and DNA polymerase 3′–5′ exonuclease activity to produce a defined target end, which is joined to a complementary adaptor to form an adapted nucleic acid. The adaptor design includes a sequence adjacent to the PAM and the PAM.
Adaptor features include UMI or SID barcodes, primer-binding sites, and a capture moiety for downstream processing. The system enables subsequent amplification, sequencing, or enrichment of the adapted DNA. The background, abstract, and summary sections are omitted from the provided content, leaving problem statements not explicitly described in patent.
Claims Coverage
The relevant claims identify one independent claim, claim 1, encompassing three inventive features directed to capturing target nucleic acids.
Generation of a target overhang
The claim uses CRISPR Cas9 cleavage and DNA polymerase 3′–5′ exonuclease activity to generate a first 5′-overhang and a first recessed 3′-end in the target nucleic acid.
Hybridization of a PAM-related adaptor
The adaptor has a second 5′-overhang capable of hybridizing to the first 5′-overhang; the second overhang comprises a sequence adjacent to the PAM and the PAM.
Formation of an adapted nucleic acid
The overhangs of the target nucleic acid and adaptor are linked at their 5′-ends and recessed 3′-ends, thereby forming an adapted nucleic acid.
Claim 1 covers the capture of a CRISPR Cas9-cleaved target through exonuclease-dependent overhang generation, adaptor hybridization, and linking to form an adapted nucleic acid. Dependent claims further describe polymerases, adaptor features, capture moieties, length constraints, and downstream operations.
Stated Advantages
Comparative gel results report expected amplicons with fewer nonspecific products than the dA-tailing comparison.
No adaptor multimers are observed in the reported comparison with dA-tailing.
Documented Applications
Capture of CRISPR Cas9-cleaved target nucleic acids from samples that also contain non-target nucleic acids.
Amplification, sequencing, or enrichment of adapted DNA.
The described comparisons use plasmid and genomic DNA targets, and the figures identify the TRAC target locus.
Interested in licensing this patent?